Pre/post effectiveness evaluation of updated additional risk minimisation measures for an orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet.

Esther ArtimeIrene ShuiIgnacio MendezStephanie Tcherny-LessenotPierre D'ArbignyNoelia AlfaroNawab Qizilbash

Published in: Pharmacoepidemiology and drug safety (2019)

Both versions of the SIP showed relatively high awareness, receipt, reading, and usage, with an overall trend for most measures to improve numerically in W2. The updated SIP did not require further changes.

Keyphrases

randomized controlled trial
systematic review
working memory
health information
healthcare